Cytokinetics | CYTK - Current Assets


Cytokinetics reported $1.19B in Current Assets for its fiscal quarter ending in September of 2026.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.27B 43.88M Sep/2026
Amgen USD 34.36B 598M Sep/2026
Arca Biopharma USD 941.49M 56.93M Sep/2026
Bayer EUR 39.6B 5.96B Sep/2026
Biogen USD 7.58B 278.7M Sep/2026
Brainstorm Cell Therapeutics USD 316K 132K Jun/2026
Bristol-Myers Squibb USD 29.77B 1.19B Sep/2026
Capricor Therapeutics USD 202.25M 39.88M Sep/2026
Cytokinetics USD 1.19B 21.34M Sep/2026
Eisai JPY 866.82B 16.2B Sep/2026
Eli Lilly USD 65.26B 591M Sep/2026
Exelixis USD 1.32B 70.8M Sep/2026
Geron USD 468.74M 17.6M Sep/2026
Halozyme Therapeutics USD 1.85B 913.71M Sep/2026
Ionis Pharmaceuticals USD 2.36B 129.77M Sep/2026
Ligand Pharmaceuticals USD 608.23M 848.88M Sep/2026
Merck USD 38.94B 2.26B Sep/2026
Novartis USD 28.75B 1.4B Sep/2026
Pfizer USD 45.01B 3.65B Sep/2026
Regeneron Pharmaceuticals USD 20.8B 2.35B Sep/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Sanofi EUR 33.21B 1.68B Sep/2026